Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (200/10 mg and 200/25 mg) (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.

Published
08 April 2015
From
Gilead press release
Kids Who Start HIV Treatment With Low CD4s Largely Regain Them

HIV-positive children who have low CD4 counts when starting treatment by and large experience a rebound to normal levels of those immune cells. After two years on HIV meds, 92 percent of the children achieved a CD4 count of 500 or above. Just nine children (1 percent) experienced an AIDS-defining illness during treatment. Children starting with fewer than 200 CD4 cells/mm3 took 1.29 years to reach a CD4 count over 500 cells/mm3.

Published
07 April 2015
From
AIDSMeds
Ritonavir concentrations not correlated with lipid levels in people with HIV taking boosted atazanavir or boosted darunavir

People taking HIV treatment based on ritonavir-boosted atazanavir and darunavir have comparable long-term increases in lipid levels, investigators from the United States report in the online edition of

Published
06 April 2015
By
Michael Carter
Chinese study sheds light on how well treatment may work as prevention in the real world

A study from the Henan province of China published recently shows that antiretroviral therapy (ART) may not be as effective at suppressing HIV and preventing onward transmission

Published
01 April 2015
By
Gus Cairns
Predictors of HIV-related peripheral neuropathy in the modern era

Researchers at major clinical centres in the U.S. have collaborated to study potential causes of peripheral neuropathy (PN) among HIV-positive people in the modern era. They recruited about 500 people who were free from PN and monitored them for an average of two years, performing extensive assessments. Taking into account many issues, statistical analysis found that there were several factors associated with an increased risk for PN.

Published
01 April 2015
From
CATIE
Most HIV-positive gay men in European survey are on HIV treatment, though fewer in the east

The large EMIS survey of gay men living in Europe has found that over 70% of respondents with HIV are taking antiretroviral therapy (ART). Of those who

Published
30 March 2015
By
Gus Cairns
More people in the UK are starting HIV treatment early, in order to reduce their risk of transmission

There is evidence of increasing interest in HIV treatment as prevention among people living with HIV in the UK, with the number of people starting treatment at

Published
25 March 2015
By
Roger Pebody
Adherence support improves ART outcomes in Kenya

The scale-up of antiretroviral therapy (ART) in Kenya is being undermined by high rates of treatment failure, investigators report in the online edition of the Journal of

Published
25 March 2015
By
Michael Carter
Experimental agents reverse HIV latency and help immune system fight HIV-infected cells

Researchers at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA, presented data on several experimental agents that may play a role in achieving

Published
24 March 2015
By
Liz Highleyman
Early antiretroviral treatment reduces, but does not eliminate HIV reservoir

Starting antiretroviral therapy (ART) very soon after infection may limit the size of the HIV 'reservoir' and delay viral rebound after treatment interruption, according to several presentations at

Published
24 March 2015
By
Liz Highleyman

Filter by country